Section Arrow
SABS.NASDAQ
- SAB Biotherapeutics
Quotes are at least 15-min delayed:2026/06/04 02:01 EDT
Regular Hours
Last
 3.36
-0.12 (-3.45%)
Day High 
3.49 
Prev. Close
3.48 
1-M High
4.5923 
Volume 
327.02K 
Bid
3.3
Ask
3.74
Day Low
3.32 
Open
3.47 
1-M Low
3.4 
Market Cap 
266.10M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.64 
20-SMA 3.73 
50-SMA 3.76 
52-W High 6.6 
52-W Low 1.6 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.58/-0.71
Enterprise Value
271.09M
Balance Sheet
Book Value Per Share
2.97
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0949-0.0149-13.57%-- 
VRAXVirax Biolabs Group Limited0.2401+0.0238+11.00%-- 
RXRXRecursion Pharmaceuticals3.47-0.14-3.88%-- 
CLDICalidi Biotherapeutics0.1656-0.0145-8.05%-- 
GOSSGossamer Bio0.1883-0.0119-5.94%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Itis focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.